8-K: Quest Diagnostics Announces Results of 2025 Annual Stockholders Meeting

Quest Diagnostics held its 2025 Annual Meeting of Stockholders on May 15, 2025, and announced the voting results for the election of directors, executive compensation, appointment of the independent accounting firm, and a stockholder proposal.

Summary

• Quest Diagnostics held its 2025 Annual Meeting of Stockholders on May 15, 2025.
• All director nominees were elected to terms expiring at the 2026 Annual Meeting.
• Robert B. Carter received 94,240,720 votes for, 298,067 against, and 262,706 abstentions.
• James E. Davis received 86,900,389 votes for, 7,692,258 against, and 208,844 abstentions.
• Luis A. Diaz, Jr., M.D. received 94,207,193 votes for, 343,702 against, and 250,599 abstentions.
• Tracey C. Doi received 94,067,950 votes for, 421,307 against, and 312,234 abstentions.
• Vicky B. Gregg received 87,477,670 votes for, 7,005,519 against, and 318,301 abstentions.
• Wright L. Lassiter, III received 94,032,686 votes for, 422,257 against, and 346,550 abstentions.
• Timothy L. Main received 91,398,895 votes for, 3,079,741 against, and 322,853 abstentions.
• Denise M. Morrison received 92,301,649 votes for, 2,152,633 against, and 347,211 abstentions.
• Gary M. Pfeiffer received 88,946,666 votes for, 5,558,376 against, and 296,442 abstentions.
• Timothy M. Ring received 87,170,357 votes for, 7,378,294 against, and 252,832 abstentions.
• The advisory resolution to approve executive officer compensation was approved with 85,922,577 votes for, 8,570,674 against, and 308,225 abstentions.
• The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for 2025 was ratified with 95,585,333 votes for, 6,869,657 against, and 501,410 abstentions.
• A stockholder proposal regarding calling a special meeting of stockholders was not approved, receiving 9,480,355 votes for, 84,410,956 against, and 910,175 abstentions.

Sentiment

Score: 7

Explanation: The document is a standard report of voting results from an annual meeting, indicating a neutral to slightly positive sentiment as corporate governance processes are being followed.

Positives

• All director nominees were successfully elected.
• Stockholders approved the executive officer compensation.
• The appointment of PricewaterhouseCoopers was ratified, ensuring continuity in auditing services.

Negatives

• A stockholder proposal regarding calling a special meeting was not approved, indicating some level of shareholder concern or disagreement.

Risks

• The rejection of the stockholder proposal could indicate underlying dissatisfaction among a portion of shareholders, which may need to be addressed by management.

Future Outlook

The newly elected directors will serve terms expiring at the 2026 Annual Meeting of Stockholders.

Industry Context

This announcement is a routine disclosure following an annual meeting, typical for publicly traded companies. It provides transparency to shareholders regarding the governance and management oversight of Quest Diagnostics.

Comparison to Industry Standards

• The voting results and matters presented are standard for annual meetings of publicly traded companies.
• Similar companies like Laboratory Corporation of America Holdings (LH) and Bio-Reference Laboratories also hold annual meetings with similar voting procedures and disclosures.

Stakeholder Impact

• Shareholders are informed about the election of directors and key decisions made at the annual meeting.
• Employees are indirectly affected by the stability and governance of the company as reflected in the voting results.

Next Steps

• The elected directors will assume their responsibilities for the upcoming year.
• Quest Diagnostics will continue to implement the ratified appointment of PricewaterhouseCoopers as their independent accounting firm.

Key Dates

Keywords

Annual Meeting, Stockholders, Director Election, Executive Compensation, PricewaterhouseCoopers, Proxy Statement, Quest Diagnostics, Voting Results